EpiCept AML Drug Gets “Exceptional Circumstances” Stamp From EU Regulators
This article was originally published in The Pink Sheet Daily
Executive SummaryRemission maintenance drug should receive formal EC approval within 67 days; new U.S. filing planned for 2009.
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.